Skip to Main Content

More than 100 Democratic members of Congress urged the Trump administration to remove pending language from the U.S.-Mexico-Canada Agreement trade agreement that would lock the U.S into at least 10 years of marketing exclusivity for biologics, a move they argue will hurt taxpayers and patients.

In a letter sent on Thursday to U.S. Trade Representative Robert Lighthizer, the lawmakers cited a provision of the deal, which has not yet been ratified, that would prevent a company seeking to sell a lower-cost version of a brand-name biologic from doing so for a decade. For this reason, they maintain the trade pact as it currently stands runs counter to efforts by President Trump to lower drug prices.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED